Borbit (Yoshindo) / Peleton (Towa Yakuhin) / Peon (Zeria Shinyaku) / Salafapinon (Choseido Pharmaceutical) / Soleng (Kyorin Rimedio) / Soleton (CJ Cheiljedang) / Soluirubin (Taiyo Pharmaceutical) / Zaltoprofen Tatsumi Kagaku (Tatsumi Kagaku) / Zatferon (Sawai Seiyaku) / Zyrogen (Yoo Young)

Categories

UNII

H8635NG3PY

CAS number

74711-43-6

Weight

Average: 298.36
Monoisotopic: 298.066365485

Chemical Formula

C₁₇H₁₄O₃S

InChI Key

MUXFZBHBYYYLTH-UHFFFAOYSA-N

InChI

InChI=1S/C17H14O3S/c1-10(17(19)20)11-6-7-15-12(8-11)9-14(18)13-4-2-3-5-16(13)21-15/h2-8,10H,9H2,1H3,(H,19,20)

IUPAC Name

2-{10-oxo-2-thiatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-6-yl}propanoic acid

SMILES

CC(C(O)=O)C1=CC=C2SC3=C(C=CC=C3)C(=O)CC2=C1

Pharmacology

Indication

Not Available

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
(4R)-limonene	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with (4R)-limonene.	Investigational
16-Bromoepiandrosterone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with 16-Bromoepiandrosterone.	Investigational
19-norandrostenedione	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with 19-norandrostenedione.	Experimental, Illicit
5-androstenedione	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with 5-androstenedione.	Experimental, Illicit
Abciximab	Zaltoprofen may increase the anticoagulant activities of Abciximab.	Approved
Abiraterone	The metabolism of Zaltoprofen can be decreased when combined with Abiraterone.	Approved
Acebutolol	Zaltoprofen may decrease the antihypertensive activities of Acebutolol.	Approved, Investigational
Aceclofenac	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Aceclofenac.	Approved, Investigational
Acemetacin	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Acemetacin.	Approved, Experimental, Investigational
Acenocoumarol	Zaltoprofen may increase the anticoagulant activities of Acenocoumarol.	Approved, Investigational
Acetyl sulfisoxazole	The metabolism of Zaltoprofen can be decreased when combined with Acetyl sulfisoxazole.	Approved, Vet Approved
Acetylsalicylic acid	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Acetylsalicylic acid.	Approved, Vet Approved
Adapalene	The risk or severity of adverse effects can be increased when Adapalene is combined with Zaltoprofen.	Approved
Alclofenac	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Alclofenac.	Approved, Withdrawn
Alclometasone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Alclometasone.	Approved
Aldosterone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Aldosterone.	Experimental, Investigational
Alendronic acid	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Alendronic acid.	Approved
Aliskiren	Zaltoprofen may decrease the antihypertensive activities of Aliskiren.	Approved, Investigational
Alminoprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Alminoprofen.	Experimental
Alprenolol	Zaltoprofen may decrease the antihypertensive activities of Alprenolol.	Approved, Withdrawn
Alprostadil	The therapeutic efficacy of Alprostadil can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Amcinonide	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Amcinonide.	Approved
Amikacin	The risk or severity of nephrotoxicity can be increased when Zaltoprofen is combined with Amikacin.	Approved, Investigational, Vet Approved
Amiloride	Zaltoprofen may decrease the antihypertensive activities of Amiloride.	Approved
Aminosalicylic Acid	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Aminosalicylic Acid.	Approved
Amlodipine	The therapeutic efficacy of Amlodipine can be decreased when used in combination with Zaltoprofen.	Approved
Ancrod	Zaltoprofen may increase the anticoagulant activities of Ancrod.	Approved, Investigational
Andrographolide	The risk or severity of adverse effects can be increased when Andrographolide is combined with Zaltoprofen.	Investigational
Androstenedione	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Androstenedione.	Experimental, Illicit
Anecortave	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Anecortave.	Investigational
anecortave acetate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with anecortave acetate.	Investigational
Anisodamine	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Anisodamine.	Investigational
Antipyrine	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Antipyrine.	Approved, Investigational
Antithrombin III human	Zaltoprofen may increase the anticoagulant activities of Antithrombin III human.	Approved
Antrafenine	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Antrafenine.	Approved
Apalutamide	The serum concentration of Zaltoprofen can be decreased when it is combined with Apalutamide.	Approved, Investigational
Apixaban	Zaltoprofen may increase the anticoagulant activities of Apixaban.	Approved
Apocynin	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Apocynin.	Investigational
Apramycin	Zaltoprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.	Experimental, Vet Approved
Apremilast	The risk or severity of adverse effects can be increased when Apremilast is combined with Zaltoprofen.	Approved, Investigational
Aprepitant	The metabolism of Zaltoprofen can be increased when combined with Aprepitant.	Approved, Investigational
Arbekacin	Zaltoprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.	Approved, Investigational
Ardeparin	Zaltoprofen may increase the anticoagulant activities of Ardeparin.	Approved, Investigational, Withdrawn
Argatroban	Zaltoprofen may increase the anticoagulant activities of Argatroban.	Approved, Investigational
Arotinolol	Zaltoprofen may decrease the antihypertensive activities of Arotinolol.	Investigational
Asenapine	Zaltoprofen may decrease the antihypertensive activities of Asenapine.	Approved
Atamestane	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Atamestane.	Investigational
Atenolol	Zaltoprofen may decrease the antihypertensive activities of Atenolol.	Approved
Azapropazone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Azapropazone.	Withdrawn
Azelastine	The risk or severity of adverse effects can be increased when Azelastine is combined with Zaltoprofen.	Approved
Azficel-T	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Azficel-T.	Approved, Investigational
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Zaltoprofen.	Approved, Investigational
Azosemide	The therapeutic efficacy of Azosemide can be decreased when used in combination with Zaltoprofen.	Investigational
Bacitracin	The risk or severity of nephrotoxicity can be increased when Zaltoprofen is combined with Bacitracin.	Approved, Vet Approved
Balsalazide	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Balsalazide.	Approved, Investigational
Becaplermin	Zaltoprofen may increase the anticoagulant activities of Becaplermin.	Approved, Investigational
Beclomethasone dipropionate	The risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Zaltoprofen.	Approved, Investigational
Befunolol	Zaltoprofen may decrease the antihypertensive activities of Befunolol.	Experimental
Bekanamycin	Zaltoprofen may decrease the excretion rate of Bekanamycin which could result in a higher serum level.	Experimental
Benazepril	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Benazepril.	Approved, Investigational
Bendazac	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Bendazac.	Experimental
Bendroflumethiazide	The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Zaltoprofen.	Approved
Benorilate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Benorilate.	Experimental
Benoxaprofen	The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Zaltoprofen.	Withdrawn
Benzthiazide	The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Zaltoprofen.	Approved
Benzydamine	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Benzydamine.	Approved
Bepridil	The therapeutic efficacy of Bepridil can be decreased when used in combination with Zaltoprofen.	Approved, Withdrawn
Beraprost	The therapeutic efficacy of Beraprost can be decreased when used in combination with Zaltoprofen.	Investigational
Betamethasone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Betamethasone.	Approved, Vet Approved
Betaxolol	Zaltoprofen may decrease the antihypertensive activities of Betaxolol.	Approved, Investigational
Betrixaban	The risk or severity of bleeding can be increased when Betrixaban is combined with Zaltoprofen.	Approved, Investigational
Bevantolol	Zaltoprofen may decrease the antihypertensive activities of Bevantolol.	Approved
Bevonium	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Bevonium.	Experimental
Bimatoprost	The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Bisoprolol	Zaltoprofen may decrease the antihypertensive activities of Bisoprolol.	Approved
Bivalirudin	Zaltoprofen may increase the anticoagulant activities of Bivalirudin.	Approved, Investigational
Bopindolol	Zaltoprofen may decrease the antihypertensive activities of Bopindolol.	Approved
Bromfenac	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Bromfenac.	Approved
Bucillamine	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Bucillamine.	Investigational
Bucindolol	Zaltoprofen may decrease the antihypertensive activities of Bucindolol.	Investigational
Budesonide	The risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Zaltoprofen.	Approved
Bufexamac	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Bufexamac.	Approved, Experimental
Bufuralol	Zaltoprofen may decrease the antihypertensive activities of Bufuralol.	Experimental, Investigational
Bumadizone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Bumadizone.	Experimental
Bumetanide	The therapeutic efficacy of Bumetanide can be decreased when used in combination with Zaltoprofen.	Approved
Bupranolol	Zaltoprofen may decrease the antihypertensive activities of Bupranolol.	Approved
Candesartan	The risk or severity of adverse effects can be increased when Candesartan is combined with Zaltoprofen.	Experimental
Candesartan cilexetil	The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Zaltoprofen.	Approved
Candoxatril	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Candoxatril.	Experimental
Capecitabine	The metabolism of Zaltoprofen can be decreased when combined with Capecitabine.	Approved, Investigational
Capsaicin	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Capsaicin.	Approved
Captopril	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Captopril.	Approved
Carbaspirin calcium	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Carbaspirin calcium.	Experimental, Investigational
Carboprost Tromethamine	The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Zaltoprofen.	Approved
Carprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Carprofen.	Approved, Vet Approved, Withdrawn
Carteolol	Zaltoprofen may decrease the antihypertensive activities of Carteolol.	Approved
Carvedilol	Zaltoprofen may decrease the antihypertensive activities of Carvedilol.	Approved, Investigational
Castanospermine	The risk or severity of adverse effects can be increased when Castanospermine is combined with Zaltoprofen.	Experimental
Celecoxib	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Celecoxib.	Approved, Investigational
Celiprolol	Zaltoprofen may decrease the antihypertensive activities of Celiprolol.	Approved, Investigational
Ceritinib	The serum concentration of Zaltoprofen can be increased when it is combined with Ceritinib.	Approved
Certoparin	Zaltoprofen may increase the anticoagulant activities of Certoparin.	Approved, Investigational
Chloroquine	The risk or severity of adverse effects can be increased when Chloroquine is combined with Zaltoprofen.	Approved, Investigational, Vet Approved
Chlorothiazide	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Zaltoprofen.	Approved, Vet Approved
Chlorphenesin	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Chlorphenesin.	Approved, Vet Approved, Withdrawn
Chlorthalidone	The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Zaltoprofen.	Approved
Cholecalciferol	The metabolism of Zaltoprofen can be decreased when combined with Cholecalciferol.	Approved, Nutraceutical
Cholestyramine	Cholestyramine can cause a decrease in the absorption of Zaltoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Choline magnesium trisalicylate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Choline magnesium trisalicylate.	Approved
Ciclesonide	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ciclesonide.	Approved, Investigational
Cilazapril	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Cilazapril.	Approved
Cimicoxib	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Cimicoxib.	Investigational
Cinoxacin	Zaltoprofen may increase the neuroexcitatory activities of Cinoxacin.	Approved, Investigational, Withdrawn
Ciprofloxacin	Zaltoprofen may increase the neuroexcitatory activities of Ciprofloxacin.	Approved, Investigational
Cisplatin	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Cisplatin.	Approved
Clobetasol	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clobetasol.	Approved, Investigational
Clobetasol propionate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clobetasol propionate.	Approved
Clobetasone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clobetasone.	Approved
Clocortolone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clocortolone.	Approved
Clodronic Acid	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clodronic Acid.	Approved, Investigational, Vet Approved
Clonixin	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clonixin.	Approved
Cloprostenol	The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Zaltoprofen.	Vet Approved
Cloranolol	Zaltoprofen may decrease the antihypertensive activities of Cloranolol.	Experimental
Colesevelam	Colesevelam can cause a decrease in the absorption of Zaltoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Colestipol	Colestipol can cause a decrease in the absorption of Zaltoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Cortexolone 17α-propionate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Cortexolone 17α-propionate.	Investigational
Corticosterone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Corticosterone.	Experimental
Cortisone acetate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Cortisone acetate.	Approved, Investigational
Crisaborole	The metabolism of Zaltoprofen can be decreased when combined with Crisaborole.	Approved, Investigational
Curcumin	The metabolism of Zaltoprofen can be decreased when combined with Curcumin.	Approved, Investigational
Cyclopenthiazide	The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Zaltoprofen.	Experimental
Cyclosporine	The risk or severity of renal failure and hypertension can be increased when Zaltoprofen is combined with Cyclosporine.	Approved, Investigational, Vet Approved
Dabigatran etexilate	Zaltoprofen may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Dabrafenib	The serum concentration of Zaltoprofen can be decreased when it is combined with Dabrafenib.	Approved, Investigational
Dalteparin	Zaltoprofen may increase the anticoagulant activities of Dalteparin.	Approved
Danaparoid	Zaltoprofen may increase the anticoagulant activities of Danaparoid.	Approved, Withdrawn
Darexaban	Zaltoprofen may increase the anticoagulant activities of Darexaban.	Investigational
Deferasirox	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Deferasirox.	Approved, Investigational
Deflazacort	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Deflazacort.	Approved, Investigational
Delapril	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Delapril.	Investigational
Delavirdine	The metabolism of Zaltoprofen can be decreased when combined with Delavirdine.	Approved
Desipramine	Zaltoprofen may decrease the antihypertensive activities of Desipramine.	Approved, Investigational
Desirudin	Zaltoprofen may increase the anticoagulant activities of Desirudin.	Approved
Desmopressin	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desmopressin.	Approved
Desonide	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desonide.	Approved, Investigational
Desoximetasone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desoximetasone.	Approved
Desoxycorticosterone acetate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desoxycorticosterone acetate.	Approved
Desoxycorticosterone Pivalate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desoxycorticosterone Pivalate.	Experimental, Vet Approved
Dexamethasone	The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Zaltoprofen.	Approved, Investigational, Vet Approved
Dexamethasone isonicotinate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Dexamethasone isonicotinate.	Vet Approved
Dexibuprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Dexibuprofen.	Approved, Investigational
Dexketoprofen	The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Zaltoprofen.	Approved, Investigational
Dexniguldipine	The therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Zaltoprofen.	Experimental
Dextran	Zaltoprofen may increase the anticoagulant activities of Dextran.	Approved, Investigational, Vet Approved
Dibekacin	Zaltoprofen may decrease the excretion rate of Dibekacin which could result in a higher serum level.	Experimental
Dibotermin alfa	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Dibotermin alfa.	Approved, Investigational
Diclofenac	The risk or severity of adverse effects can be increased when Diclofenac is combined with Zaltoprofen.	Approved, Vet Approved
Dicoumarol	Zaltoprofen may increase the anticoagulant activities of Dicoumarol.	Approved
Difenpiramide	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Difenpiramide.	Experimental
Diflorasone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Diflorasone.	Approved
Diflunisal	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Diflunisal.	Approved, Investigational
Difluocortolone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Difluocortolone.	Approved, Investigational, Withdrawn
Difluprednate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Difluprednate.	Approved
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Zaltoprofen.	Approved
Dihydrostreptomycin	Zaltoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.	Investigational, Vet Approved
Diltiazem	The therapeutic efficacy of Diltiazem can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Dinoprost	The therapeutic efficacy of Dinoprost can be decreased when used in combination with Zaltoprofen.	Investigational
Dinoprost Tromethamine	The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Zaltoprofen.	Approved, Vet Approved
Dinoprostone	The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Zaltoprofen.	Approved
Dosulepin	The metabolism of Zaltoprofen can be decreased when combined with Dosulepin.	Approved
Doxazosin	The therapeutic efficacy of Doxazosin can be decreased when used in combination with Zaltoprofen.	Approved
Drospirenone	Zaltoprofen may increase the hyperkalemic activities of Drospirenone.	Approved
Droxicam	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Droxicam.	Withdrawn
Duvelisib	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Duvelisib.	Investigational
E-6201	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with E-6201.	Investigational
Edetic Acid	Zaltoprofen may increase the anticoagulant activities of Edetic Acid.	Approved, Vet Approved
Edoxaban	Zaltoprofen may increase the anticoagulant activities of Edoxaban.	Approved
Efavirenz	The metabolism of Zaltoprofen can be decreased when combined with Efavirenz.	Approved, Investigational
Efonidipine	The therapeutic efficacy of Efonidipine can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Enalapril	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Enalapril.	Approved, Vet Approved
Enalaprilat	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Enalaprilat.	Approved
Enoxacin	Zaltoprofen may increase the neuroexcitatory activities of Enoxacin.	Approved, Investigational
Enoxaparin	Zaltoprofen may increase the anticoagulant activities of Enoxaparin.	Approved
Enprostil	The therapeutic efficacy of Enprostil can be decreased when used in combination with Zaltoprofen.	Experimental
Epanolol	Zaltoprofen may decrease the antihypertensive activities of Epanolol.	Experimental
Epirizole	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Epirizole.	Approved
Epitizide	The therapeutic efficacy of Epitizide can be decreased when used in combination with Zaltoprofen.	Experimental
Eplerenone	Zaltoprofen may decrease the antihypertensive activities of Eplerenone.	Approved
Epoprostenol	The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Zaltoprofen.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Eprosartan is combined with Zaltoprofen.	Approved
Equilenin	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Equilenin.	Experimental
Equilin	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Equilin.	Approved
Esatenolol	Zaltoprofen may decrease the antihypertensive activities of Esatenolol.	Experimental
Esmolol	Zaltoprofen may decrease the antihypertensive activities of Esmolol.	Approved
Estrone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Estrone.	Approved
Estrone sulfate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Estrone sulfate.	Approved
Etacrynic acid	The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Etanercept	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Etanercept.	Approved, Investigational
Ethenzamide	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ethenzamide.	Experimental
Ethyl biscoumacetate	Zaltoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.	Withdrawn
Etidronic acid	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Etidronic acid.	Approved
Etodolac	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Etodolac.	Approved, Investigational, Vet Approved
Etofenamate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Etofenamate.	Approved, Investigational
Etoricoxib	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Etoricoxib.	Approved, Investigational
Etravirine	The metabolism of Zaltoprofen can be decreased when combined with Etravirine.	Approved
Evening primrose oil	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Evening primrose oil.	Investigational, Nutraceutical
Exisulind	The risk or severity of adverse effects can be increased when Exisulind is combined with Zaltoprofen.	Investigational
Felbinac	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Felbinac.	Experimental
Felodipine	The therapeutic efficacy of Felodipine can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Fenbufen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fenbufen.	Approved
Fenoprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fenoprofen.	Approved
Fenprostalene	The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Zaltoprofen.	Vet Approved
Fentiazac	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fentiazac.	Experimental
Feprazone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Feprazone.	Experimental
Ferulic acid	Zaltoprofen may increase the anticoagulant activities of Ferulic acid.	Experimental
Fimasartan	The risk or severity of adverse effects can be increased when Fimasartan is combined with Zaltoprofen.	Approved, Investigational
Fleroxacin	Zaltoprofen may increase the neuroexcitatory activities of Fleroxacin.	Approved
Floctafenine	The risk or severity of adverse effects can be increased when Floctafenine is combined with Zaltoprofen.	Approved, Withdrawn
Floxuridine	The metabolism of Zaltoprofen can be decreased when combined with Floxuridine.	Approved
Fluasterone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluasterone.	Investigational
Fluconazole	The metabolism of Zaltoprofen can be decreased when combined with Fluconazole.	Approved, Investigational
Fludrocortisone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fludrocortisone.	Approved, Investigational
Fluindione	Zaltoprofen may increase the anticoagulant activities of Fluindione.	Approved, Investigational
Flumequine	Zaltoprofen may increase the neuroexcitatory activities of Flumequine.	Withdrawn
Flumethasone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Flumethasone.	Approved, Vet Approved
Flunisolide	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Flunisolide.	Approved, Investigational
Flunixin	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Flunixin.	Vet Approved
Flunoxaprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Flunoxaprofen.	Experimental
Fluocinolone Acetonide	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluocinolone Acetonide.	Approved, Investigational, Vet Approved
Fluocinonide	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluocinonide.	Approved, Investigational
Fluocortolone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluocortolone.	Approved, Withdrawn
Fluorometholone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluorometholone.	Approved, Investigational
Fluorouracil	The metabolism of Zaltoprofen can be decreased when combined with Fluorouracil.	Approved
Fluprednidene	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluprednidene.	Approved, Withdrawn
Fluprednisolone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluprednisolone.	Approved
Fluprostenol	The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Zaltoprofen.	Vet Approved
Flurandrenolide	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Flurandrenolide.	Approved
Flurbiprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Flurbiprofen.	Approved, Investigational
Fluticasone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluticasone.	Approved, Experimental, Investigational
Fluticasone furoate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluticasone furoate.	Approved
Fluticasone propionate	The risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Zaltoprofen.	Approved
Folic Acid	The therapeutic efficacy of Folic Acid can be decreased when used in combination with Zaltoprofen.	Approved, Nutraceutical, Vet Approved
Fondaparinux	Zaltoprofen may increase the anticoagulant activities of Fondaparinux sodium.	Approved, Investigational
Forasartan	The risk or severity of adverse effects can be increased when Forasartan is combined with Zaltoprofen.	Experimental
Formestane	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Formestane.	Approved, Investigational, Withdrawn
Fosinopril	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Zaltoprofen is combined with Fosinopril.	Approved
Fosphenytoin	The metabolism of Zaltoprofen can be increased when combined with Fosphenytoin.	Approved, Investigational
Framycetin	Zaltoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.	Approved
Furosemide	The therapeutic efficacy of Furosemide can be decreased when used in combination with Zaltoprofen.	Approved, Vet Approved
Gabexate	Zaltoprofen may increase the anticoagulant activities of Gabexate.	Investigational
Garenoxacin	Zaltoprofen may increase the neuroexcitatory activities of Garenoxacin.	Investigational
Gatifloxacin	Zaltoprofen may increase the neuroexcitatory activities of Gatifloxacin.	Approved, Investigational
Gemeprost	The therapeutic efficacy of Gemeprost can be decreased when used in combination with Zaltoprofen.	Approved, Withdrawn
Gemfibrozil	The metabolism of Zaltoprofen can be decreased when combined with Gemfibrozil.	Approved
Gemifloxacin	Zaltoprofen may increase the neuroexcitatory activities of Gemifloxacin.	Approved, Investigational
Geneticin	Zaltoprofen may decrease the excretion rate of Geneticin which could result in a higher serum level.	Experimental
Gentamicin	Zaltoprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.	Approved, Vet Approved
GENTAMICIN C1A	Zaltoprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.	Experimental
Ginseng	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ginseng.	Approved, Investigational, Nutraceutical
Glipizide	The protein binding of Glipizide can be decreased when combined with Zaltoprofen.	Approved, Investigational
Glyburide	The protein binding of Glyburide can be decreased when combined with Zaltoprofen.	Approved
Grepafloxacin	Zaltoprofen may increase the neuroexcitatory activities of Grepafloxacin.	Approved, Investigational, Withdrawn
Guacetisal	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Guacetisal.	Experimental
Guanfacine	The therapeutic efficacy of Guanfacine can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Halcinonide	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Halcinonide.	Approved, Investigational, Withdrawn
Haloperidol	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Haloperidol.	Approved
HE3286	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with HE3286.	Investigational
Heparin	Zaltoprofen may increase the anticoagulant activities of Heparin.	Approved, Investigational
Higenamine	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Higenamine.	Investigational
Hydralazine	Zaltoprofen may decrease the antihypertensive activities of Hydralazine.	Approved
Hydrochlorothiazide	The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Zaltoprofen.	Approved, Vet Approved
Hydrocortisone	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Zaltoprofen.	Approved, Vet Approved
Hydrocortisone acetate	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Zaltoprofen.	Approved, Vet Approved
Hydrocortisone butyrate	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Zaltoprofen.	Approved, Vet Approved
Hydroflumethiazide	The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Hygromycin B	Zaltoprofen may decrease the excretion rate of Hygromycin B which could result in a higher serum level.	Vet Approved
Ibandronate	The risk or severity of gastrointestinal bleeding can be increased when Zaltoprofen is combined with Ibandronate.	Approved, Investigational
Ibuprofen	The risk or severity of adverse effects can be increased when Ibuprofen is combined with Zaltoprofen.	Approved
Ibuproxam	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ibuproxam.	Withdrawn
Icatibant	The risk or severity of adverse effects can be increased when Icatibant is combined with Zaltoprofen.	Approved, Investigational
Icosapent	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Icosapent.	Approved, Nutraceutical
Idraparinux	Zaltoprofen may increase the anticoagulant activities of Idraparinux.	Investigational
Iloprost	The therapeutic efficacy of Iloprost can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Imidapril	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Imidapril.	Investigational
Imidazole salicylate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Imidazole salicylate.	Experimental
Indapamide	The therapeutic efficacy of Indapamide can be decreased when used in combination with Zaltoprofen.	Approved
Indenolol	Zaltoprofen may decrease the antihypertensive activities of Indenolol.	Withdrawn
Indinavir	The metabolism of Zaltoprofen can be decreased when combined with Indinavir.	Approved
Indobufen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Indobufen.	Investigational
Indomethacin	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Indomethacin.	Approved, Investigational
Indoprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Indoprofen.	Withdrawn
Irbesartan	The metabolism of Zaltoprofen can be decreased when combined with Irbesartan.	Approved, Investigational
Isepamicin	Zaltoprofen may decrease the excretion rate of Isepamicin which could result in a higher serum level.	Experimental
Isoxicam	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Isoxicam.	Withdrawn
Isradipine	The therapeutic efficacy of Isradipine can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Istaroxime	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Istaroxime.	Investigational
Kanamycin	Zaltoprofen may decrease the excretion rate of Kanamycin which could result in a higher serum level.	Approved, Investigational, Vet Approved
Kebuzone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Kebuzone.	Experimental
Ketoconazole	The metabolism of Zaltoprofen can be decreased when combined with Ketoconazole.	Approved, Investigational
Ketoprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ketoprofen.	Approved, Vet Approved
Ketorolac	The risk or severity of adverse effects can be increased when Ketorolac is combined with Zaltoprofen.	Approved
Labetalol	Zaltoprofen may decrease the antihypertensive activities of Labetalol.	Approved
Lacidipine	The therapeutic efficacy of Lacidipine can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Landiolol	Zaltoprofen may decrease the antihypertensive activities of Landiolol.	Investigational
Latanoprost	The therapeutic efficacy of Latanoprost can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Latanoprostene Bunod	The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Leflunomide	The metabolism of Zaltoprofen can be decreased when combined with Leflunomide.	Approved, Investigational
Lepirudin	Zaltoprofen may increase the anticoagulant activities of Lepirudin.	Approved
Lercanidipine	The therapeutic efficacy of Lercanidipine can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Letaxaban	Zaltoprofen may increase the anticoagulant activities of Letaxaban.	Investigational
Levobetaxolol	Zaltoprofen may decrease the antihypertensive activities of Levobetaxolol.	Approved, Investigational
Levobunolol	Zaltoprofen may decrease the antihypertensive activities of Levobunolol.	Approved
Levofloxacin	Zaltoprofen may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Limaprost	The therapeutic efficacy of Limaprost can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Lisinopril	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Lisinopril.	Approved, Investigational
Lisofylline	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Lisofylline.	Investigational
Lithium cation	The serum concentration of Lithium can be increased when it is combined with Zaltoprofen.	Experimental
Lobeglitazone	The metabolism of Zaltoprofen can be decreased when combined with Lobeglitazone.	Approved, Investigational
Lomefloxacin	Zaltoprofen may increase the neuroexcitatory activities of Lomefloxacin.	Approved, Investigational
Lonazolac	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Lonazolac.	Experimental
Lornoxicam	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Lornoxicam.	Approved, Investigational
Losartan	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Zaltoprofen.	Approved
Loteprednol	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Loteprednol.	Approved
Lovastatin	The metabolism of Zaltoprofen can be decreased when combined with Lovastatin.	Approved, Investigational
Loxoprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Loxoprofen.	Approved, Investigational
Lubiprostone	The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Lumacaftor	The serum concentration of Zaltoprofen can be decreased when it is combined with Lumacaftor.	Approved
Lumiracoxib	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Lumiracoxib.	Approved, Investigational
Luprostiol	The therapeutic efficacy of Luprostiol can be decreased when used in combination with Zaltoprofen.	Vet Approved
Magnesium salicylate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Magnesium salicylate.	Approved
Manidipine	The therapeutic efficacy of Manidipine can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Masoprocol	The risk or severity of adverse effects can be increased when Masoprocol is combined with Zaltoprofen.	Approved, Investigational
ME-609	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with ME-609.	Investigational
Meclofenamic acid	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Meclofenamic acid.	Approved, Vet Approved
Medrysone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Medrysone.	Approved
Mefenamic acid	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Mefenamic acid.	Approved
Melagatran	Zaltoprofen may increase the anticoagulant activities of Melagatran.	Experimental
Melengestrol	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Melengestrol.	Vet Approved
Meloxicam	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Meloxicam.	Approved, Vet Approved
Mepindolol	Zaltoprofen may decrease the antihypertensive activities of Mepindolol.	Experimental
Mesalazine	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Mesalazine.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Metamizole is combined with Zaltoprofen.	Approved, Investigational, Withdrawn
Methotrexate	The serum concentration of Methotrexate can be increased when it is combined with Zaltoprofen.	Approved
Methyclothiazide	The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Zaltoprofen.	Approved
Methylprednisolone	The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Zaltoprofen.	Approved, Vet Approved
Metipranolol	Zaltoprofen may decrease the antihypertensive activities of Metipranolol.	Approved
Metolazone	The therapeutic efficacy of Metolazone can be decreased when used in combination with Zaltoprofen.	Approved
Metoprolol	Zaltoprofen may decrease the antihypertensive activities of Metoprolol.	Approved, Investigational
Mibefradil	The therapeutic efficacy of Mibefradil can be decreased when used in combination with Zaltoprofen.	Investigational, Withdrawn
Micronomicin	Zaltoprofen may decrease the excretion rate of Micronomicin which could result in a higher serum level.	Experimental
Midostaurin	The metabolism of Zaltoprofen can be decreased when combined with Midostaurin.	Approved, Investigational
Mifamurtide	The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Zaltoprofen.	Approved, Experimental
Mifepristone	The serum concentration of Zaltoprofen can be increased when it is combined with Mifepristone.	Approved, Investigational
Minoxidil	The therapeutic efficacy of Minoxidil can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Misoprostol	The therapeutic efficacy of Misoprostol can be decreased when used in combination with Zaltoprofen.	Approved
Mizoribine	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Mizoribine.	Investigational
Moexipril	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Moexipril.	Approved
Mofebutazone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Mofebutazone.	Experimental
Mometasone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Mometasone.	Approved, Vet Approved
Morniflumate	The risk or severity of adverse effects can be increased when Morniflumate is combined with Zaltoprofen.	Approved
Moxifloxacin	Zaltoprofen may increase the neuroexcitatory activities of Moxifloxacin.	Approved, Investigational
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Zaltoprofen.	Approved, Investigational
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zaltoprofen.	Approved
Nabilone	The metabolism of Zaltoprofen can be decreased when combined with Nabilone.	Approved, Investigational
Nabumetone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Nabumetone.	Approved
Nadolol	Zaltoprofen may decrease the antihypertensive activities of Nadolol.	Approved
Nadroparin	Zaltoprofen may increase the anticoagulant activities of Nadroparin.	Approved, Investigational
Nafamostat	Zaltoprofen may increase the anticoagulant activities of Nafamostat.	Approved, Investigational
Naftifine	The risk or severity of adverse effects can be increased when Naftifine is combined with Zaltoprofen.	Approved
Naftopidil	The therapeutic efficacy of Naftopidil can be decreased when used in combination with Zaltoprofen.	Investigational
Nalidixic Acid	Zaltoprofen may increase the neuroexcitatory activities of Nalidixic Acid.	Approved, Investigational
Naproxen	The risk or severity of adverse effects can be increased when Naproxen is combined with Zaltoprofen.	Approved, Vet Approved
NCX 1022	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with NCX 1022.	Investigational
Neamine	Zaltoprofen may decrease the excretion rate of Neamine which could result in a higher serum level.	Experimental
Nebivolol	Zaltoprofen may decrease the antihypertensive activities of Nebivolol.	Approved, Investigational
Nemonoxacin	Zaltoprofen may increase the neuroexcitatory activities of Nemonoxacin.	Investigational
Neomycin	The risk or severity of nephrotoxicity can be increased when Zaltoprofen is combined with Neomycin.	Approved, Vet Approved
Nepafenac	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Nepafenac.	Approved, Investigational
Netilmicin	Zaltoprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.	Approved, Investigational
Nicardipine	The therapeutic efficacy of Nicardipine can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Nifenazone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Nifenazone.	Experimental
Niflumic Acid	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Niflumic Acid.	Approved
Niguldipine	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Zaltoprofen.	Experimental
Nilvadipine	The therapeutic efficacy of Nilvadipine can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Nimesulide	The risk or severity of adverse effects can be increased when Nimesulide is combined with Zaltoprofen.	Approved, Investigational, Withdrawn
Nimodipine	The therapeutic efficacy of Nimodipine can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Nisoldipine	The therapeutic efficacy of Nisoldipine can be decreased when used in combination with Zaltoprofen.	Approved
Nitrendipine	The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Nitroaspirin	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Nitroaspirin.	Investigational
Norfloxacin	Zaltoprofen may increase the neuroexcitatory activities of Norfloxacin.	Approved
Ofloxacin	Zaltoprofen may increase the neuroexcitatory activities of Ofloxacin.	Approved
Oleoyl-estrone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Oleoyl-estrone.	Investigational
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Zaltoprofen.	Approved, Investigational
Olopatadine	The risk or severity of adverse effects can be increased when Olopatadine is combined with Zaltoprofen.	Approved
Olsalazine	Zaltoprofen may increase the nephrotoxic activities of Olsalazine.	Approved
Omacetaxine mepesuccinate	The risk or severity of bleeding can be increased when Zaltoprofen is combined with Omacetaxine mepesuccinate.	Approved, Investigational
Omapatrilat	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Omapatrilat.	Investigational
Orgotein	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Orgotein.	Vet Approved
Otamixaban	Zaltoprofen may increase the anticoagulant activities of Otamixaban.	Investigational
Oxaprozin	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Oxaprozin.	Approved
Oxolinic acid	Zaltoprofen may increase the neuroexcitatory activities of Oxolinic acid.	Experimental
Oxprenolol	Zaltoprofen may decrease the antihypertensive activities of Oxprenolol.	Approved
Oxyphenbutazone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Zaltoprofen.	Approved, Withdrawn
Palmidrol	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Palmidrol.	Experimental, Nutraceutical
Pamidronate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pamidronate.	Approved
Paramethasone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Paramethasone.	Approved
Parecoxib	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Parecoxib.	Approved
Paromomycin	The risk or severity of nephrotoxicity can be increased when Zaltoprofen is combined with Paromomycin.	Approved, Investigational
Parthenolide	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Parthenolide.	Approved, Investigational
Pazufloxacin	Zaltoprofen may increase the neuroexcitatory activities of Pazufloxacin.	Investigational
Pefloxacin	Zaltoprofen may increase the neuroexcitatory activities of Pefloxacin.	Approved
Penbutolol	Zaltoprofen may decrease the antihypertensive activities of Penbutolol.	Approved, Investigational
Pentaerythritol Tetranitrate	Zaltoprofen may increase the anticoagulant activities of Pentaerythritol Tetranitrate.	Approved
Pentosan Polysulfate	Zaltoprofen may increase the anticoagulant activities of Pentosan Polysulfate.	Approved
Perindopril	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Perindopril.	Approved
Phenindione	Zaltoprofen may increase the anticoagulant activities of Phenindione.	Approved, Investigational
Phenprocoumon	Zaltoprofen may increase the anticoagulant activities of Phenprocoumon.	Approved, Investigational
Phenylbutazone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Phenylbutazone.	Approved, Vet Approved
Phenytoin	The metabolism of Zaltoprofen can be increased when combined with Phenytoin.	Approved, Vet Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zaltoprofen.	Approved, Investigational
Pindolol	Zaltoprofen may decrease the antihypertensive activities of Pindolol.	Approved, Investigational
Pipemidic acid	Zaltoprofen may increase the neuroexcitatory activities of Pipemidic acid.	Experimental
Piretanide	The therapeutic efficacy of Piretanide can be decreased when used in combination with Zaltoprofen.	Approved
Pirfenidone	The risk or severity of adverse effects can be increased when Pirfenidone is combined with Zaltoprofen.	Approved, Investigational
Piromidic acid	Zaltoprofen may increase the neuroexcitatory activities of Piromidic acid.	Experimental
Piroxicam	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Piroxicam.	Approved, Investigational
Pirprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pirprofen.	Experimental
Pitolisant	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pitolisant.	Approved, Investigational
Platelet Activating Factor	Zaltoprofen may decrease the antihypertensive activities of Platelet Activating Factor.	Experimental
Plazomicin	Zaltoprofen may decrease the excretion rate of Plazomicin which could result in a higher serum level.	Approved, Investigational
Polythiazide	The therapeutic efficacy of Polythiazide can be decreased when used in combination with Zaltoprofen.	Approved
Pomalidomide	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pomalidomide.	Approved
Potassium Citrate	Zaltoprofen may increase the anticoagulant activities of Potassium Citrate.	Approved, Investigational, Vet Approved
Practolol	Zaltoprofen may decrease the antihypertensive activities of Practolol.	Approved
Pralatrexate	The serum concentration of Pralatrexate can be increased when it is combined with Zaltoprofen.	Approved, Investigational
Pranoprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pranoprofen.	Experimental, Investigational
Prasterone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Prasterone.	Approved, Investigational, Nutraceutical
Prasterone sulfate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Prasterone sulfate.	Investigational
Prednicarbate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Prednicarbate.	Approved, Investigational
Prednisolone	The risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Zaltoprofen.	Approved, Vet Approved
Prednisone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Prednisone.	Approved, Vet Approved
Pregnenolone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pregnenolone.	Approved, Experimental, Investigational
Primidone	The metabolism of Zaltoprofen can be increased when combined with Primidone.	Approved, Vet Approved
Probenecid	The serum concentration of Zaltoprofen can be increased when it is combined with Probenecid.	Approved, Investigational
Proglumetacin	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Proglumetacin.	Experimental
Propacetamol	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Propacetamol.	Approved, Investigational
Propafenone	Zaltoprofen may decrease the antihypertensive activities of Propafenone.	Approved
Propranolol	Zaltoprofen may decrease the antihypertensive activities of Propranolol.	Approved, Investigational
Propyphenazone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Propyphenazone.	Experimental
Proquazone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Proquazone.	Experimental
Prostaglandin B2	The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Zaltoprofen.	Experimental
Prostaglandin G2	The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Zaltoprofen.	Experimental
Prostalene	The therapeutic efficacy of Prostalene can be decreased when used in combination with Zaltoprofen.	Vet Approved
Protein C	Zaltoprofen may increase the anticoagulant activities of Protein C.	Approved
Protein S human	Zaltoprofen may increase the anticoagulant activities of Protein S human.	Approved
Protocatechualdehyde	Zaltoprofen may increase the anticoagulant activities of Protocatechualdehyde.	Approved
Prulifloxacin	Zaltoprofen may increase the neuroexcitatory activities of Prulifloxacin.	Investigational
PTC299	The risk or severity of adverse effects can be increased when PTC299 is combined with Zaltoprofen.	Investigational
Puromycin	Zaltoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.	Experimental
Pyrimethamine	The metabolism of Zaltoprofen can be decreased when combined with Pyrimethamine.	Approved, Investigational, Vet Approved
Quinapril	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Quinapril.	Approved, Investigational
Quinethazone	The therapeutic efficacy of Quinethazone can be decreased when used in combination with Zaltoprofen.	Approved
Quinine	The metabolism of Zaltoprofen can be decreased when combined with Quinine.	Approved
Ramipril	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ramipril.	Approved
Rescinnamine	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Rescinnamine.	Approved
Resveratrol	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Resveratrol.	Approved, Experimental, Investigational
Reviparin	Zaltoprofen may increase the anticoagulant activities of Reviparin.	Approved, Investigational
Ribostamycin	Zaltoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.	Approved, Investigational
Rifapentine	The metabolism of Zaltoprofen can be increased when combined with Rifapentine.	Approved, Investigational
Rimexolone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Rimexolone.	Approved
Risedronate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Risedronate.	Approved, Investigational
Rivaroxaban	Zaltoprofen may increase the anticoagulant activities of Rivaroxaban.	Approved
Rofecoxib	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Rofecoxib.	Approved, Investigational, Withdrawn
Rosoxacin	Zaltoprofen may increase the neuroexcitatory activities of Rosoxacin.	Approved, Investigational
Rucaparib	The metabolism of Zaltoprofen can be decreased when combined with Rucaparib.	Approved, Investigational
Rufloxacin	Zaltoprofen may increase the neuroexcitatory activities of Rufloxacin.	Experimental
Sacubitril	The risk or severity of adverse effects can be increased when Sacubitril is combined with Zaltoprofen.	Approved
Salicylamide	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Salicylamide.	Approved
Salicylic acid	The risk or severity of adverse effects can be increased when Salicylic acid is combined with Zaltoprofen.	Approved, Investigational, Vet Approved
Salsalate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Salsalate.	Approved
Saprisartan	The risk or severity of adverse effects can be increased when Saprisartan is combined with Zaltoprofen.	Experimental
Saralasin	The risk or severity of adverse effects can be increased when Saralasin is combined with Zaltoprofen.	Investigational
Sarilumab	Sarilumab may increase the immunosuppressive activities of Zaltoprofen.	Approved, Investigational
Secobarbital	The metabolism of Zaltoprofen can be increased when combined with Secobarbital.	Approved, Vet Approved
Seliciclib	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Seliciclib.	Investigational
Semapimod	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Semapimod.	Investigational
Seratrodast	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Seratrodast.	Approved
Serrapeptase	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Serrapeptase.	Investigational
Sildenafil	The metabolism of Zaltoprofen can be decreased when combined with Sildenafil.	Approved, Investigational
Sisomicin	Zaltoprofen may decrease the excretion rate of Sisomicin which could result in a higher serum level.	Investigational
Sitafloxacin	Zaltoprofen may increase the neuroexcitatory activities of Sitafloxacin.	Experimental, Investigational
Sodium Citrate	The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Sodium Citrate.	Approved, Investigational
Sodium phosphate, monobasic	The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Zaltoprofen.	Approved
Sorafenib	The metabolism of Zaltoprofen can be decreased when combined with Sorafenib.	Approved, Investigational
Sotalol	Zaltoprofen may decrease the antihypertensive activities of Sotalol.	Approved
Sparfloxacin	Zaltoprofen may increase the neuroexcitatory activities of Sparfloxacin.	Approved, Investigational
Spirapril	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Spirapril.	Approved
Spironolactone	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Zaltoprofen is combined with Spironolactone.	Approved
SRT501	The risk or severity of adverse effects can be increased when SRT501 is combined with Zaltoprofen.	Investigational
Streptomycin	Zaltoprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.	Approved, Vet Approved
Sulfadiazine	The metabolism of Zaltoprofen can be decreased when combined with Sulfadiazine.	Approved, Investigational, Vet Approved
Sulfamethoxazole	The metabolism of Zaltoprofen can be decreased when combined with Sulfamethoxazole.	Approved
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Zaltoprofen.	Approved
Sulfisoxazole	The metabolism of Zaltoprofen can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sulindac	The risk or severity of adverse effects can be increased when Sulindac is combined with Zaltoprofen.	Approved, Investigational
Sulodexide	Zaltoprofen may increase the anticoagulant activities of Sulodexide.	Approved, Investigational
Sulprostone	The therapeutic efficacy of Sulprostone can be decreased when used in combination with Zaltoprofen.	Investigational
Suprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Suprofen.	Approved, Withdrawn
Suxibuzone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Suxibuzone.	Experimental
Tacrolimus	Zaltoprofen may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational
Tafluprost	The therapeutic efficacy of Tafluprost can be decreased when used in combination with Zaltoprofen.	Approved
Talinolol	Zaltoprofen may decrease the antihypertensive activities of Talinolol.	Investigational
Talniflumate	The risk or severity of adverse effects can be increased when Talniflumate is combined with Zaltoprofen.	Approved
Tarenflurbil	The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Zaltoprofen.	Investigational
Tasosartan	The risk or severity of adverse effects can be increased when Tasosartan is combined with Zaltoprofen.	Approved
Technetium Tc-99m etidronate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Technetium Tc-99m etidronate.	Approved
Technetium Tc-99m medronate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Technetium Tc-99m medronate.	Approved
Telmisartan	The risk or severity of adverse effects can be increased when Telmisartan is combined with Zaltoprofen.	Approved, Investigational
Temafloxacin	Zaltoprofen may increase the neuroexcitatory activities of Temafloxacin.	Withdrawn
Temocapril	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Temocapril.	Experimental, Investigational
Tenidap	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tenidap.	Experimental
Tenofovir disoproxil	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tenofovir disoproxil.	Approved, Investigational
Tenoxicam	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tenoxicam.	Approved
Tepoxalin	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tepoxalin.	Vet Approved
Terbutaline	Zaltoprofen may decrease the antihypertensive activities of Terbutaline.	Approved
Teriflunomide	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Teriflunomide.	Approved
Tertatolol	Zaltoprofen may decrease the antihypertensive activities of Tertatolol.	Experimental
Tetrahydropalmatine	The therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Zaltoprofen.	Investigational
Tiaprofenic acid	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tiaprofenic acid.	Approved
Ticagrelor	The metabolism of Zaltoprofen can be decreased when combined with Ticagrelor.	Approved
Ticlopidine	The metabolism of Zaltoprofen can be decreased when combined with Ticlopidine.	Approved
Tiludronic acid	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tiludronic acid.	Approved, Investigational, Vet Approved
Timolol	Zaltoprofen may decrease the antihypertensive activities of Timolol.	Approved
Tinoridine	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tinoridine.	Investigational
Tixocortol	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tixocortol.	Approved, Withdrawn
Tobramycin	Zaltoprofen may decrease the excretion rate of Tobramycin which could result in a higher serum level.	Approved, Investigational
Tolbutamide	The metabolism of Zaltoprofen can be decreased when combined with Tolbutamide.	Approved, Investigational
Tolfenamic Acid	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tolfenamic Acid.	Approved, Investigational
Tolmetin	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tolmetin.	Approved
Topiroxostat	The metabolism of Zaltoprofen can be decreased when combined with Topiroxostat.	Approved, Investigational
Torasemide	The therapeutic efficacy of Torasemide can be decreased when used in combination with Zaltoprofen.	Approved
Trandolapril	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Trandolapril.	Approved
Travoprost	The therapeutic efficacy of Travoprost can be decreased when used in combination with Zaltoprofen.	Approved
Treprostinil	The risk or severity of adverse effects can be increased when Treprostinil is combined with Zaltoprofen.	Approved, Investigational
Triamcinolone	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Triamcinolone.	Approved, Vet Approved
Triamterene	Zaltoprofen may decrease the antihypertensive activities of Triamterene.	Approved
Tribenoside	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tribenoside.	Experimental
Trichlormethiazide	The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Zaltoprofen.	Approved, Vet Approved
Trimethoprim	The metabolism of Zaltoprofen can be decreased when combined with Trimethoprim.	Approved, Vet Approved
Triptolide	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Triptolide.	Investigational
Trolamine salicylate	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Trolamine salicylate.	Approved
Trovafloxacin	Zaltoprofen may increase the neuroexcitatory activities of Trovafloxacin.	Approved, Investigational, Withdrawn
Troxerutin	Zaltoprofen may increase the anticoagulant activities of Troxerutin.	Investigational
Ulobetasol	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ulobetasol.	Approved
Unoprostone	The therapeutic efficacy of Unoprostone can be decreased when used in combination with Zaltoprofen.	Approved, Investigational
Valdecoxib	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Valdecoxib.	Approved, Investigational, Withdrawn
Valsartan	The metabolism of Zaltoprofen can be decreased when combined with Valsartan.	Approved, Investigational
Vancomycin	Zaltoprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level.	Approved
Voriconazole	The metabolism of Zaltoprofen can be decreased when combined with Voriconazole.	Approved, Investigational
Warfarin	Zaltoprofen may increase the anticoagulant activities of Warfarin.	Approved
Ximelagatran	Zaltoprofen may increase the anticoagulant activities of Ximelagatran.	Approved, Investigational, Withdrawn
Zafirlukast	The metabolism of Zaltoprofen can be decreased when combined with Zafirlukast.	Approved, Investigational
Zileuton	The risk or severity of adverse effects can be increased when Zileuton is combined with Zaltoprofen.	Approved, Investigational, Withdrawn
Zofenopril	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Zofenopril.	Experimental
Zoledronic acid	The risk or severity of gastrointestinal bleeding can be increased when Zaltoprofen is combined with Zoledronic acid.	Approved
Zomepirac	The risk or severity of adverse effects can be increased when Zomepirac is combined with Zaltoprofen.	Withdrawn

Food Interactions

Not Available

References

General References

Hirate K, Uchida A, Ogawa Y, Arai T, Yoda K: Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors. Neurosci Res. 2006 Apr;54(4):288-94. Epub 2006 Feb 13. [PubMed:16473424]

External Links

KEGG Drug: D01547
PubChem Compound: 5720
PubChem Substance: 347827786
ChemSpider: 5518
ChEBI: 32306
ChEMBL: CHEMBL1765291
Wikipedia: Zaltoprofen

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
Not Available	Unknown Status	Treatment	Injuries, Whiplash	1

Pharmacoeconomics

Manufacturers: Not Available
Packagers: Not Available
Dosage forms: Not Available
Prices: Not Available
Patents: Not Available

Properties

State

Solid

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.0139 mg/mL	ALOGPS
logP	3.55	ALOGPS
logP	3.76	ChemAxon
logS	-4.3	ALOGPS
pKa (Strongest Acidic)	3.67	ChemAxon
pKa (Strongest Basic)	-7.6	ChemAxon
Physiological Charge	-1	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	54.37 Å²	ChemAxon
Rotatable Bond Count	2	ChemAxon
Refractivity	83.69 m³·mol^-1	ChemAxon
Polarizability	31.16 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Taxonomy

Description: This compound belongs to the class of organic compounds known as dibenzothiepins. These are compounds containing a dibenzothiepin moiety, which consists of two benzene connected by a thiepine ring.
Kingdom: Organic compounds
Super Class: Organoheterocyclic compounds
Class: Benzothiepins
Sub Class: Dibenzothiepins
Direct Parent: Dibenzothiepins
Alternative Parents: Diarylthioethers / Aryl alkyl ketones / Vinylogous thioesters / Benzenoids / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
Substituents: Dibenzothiepin / Diarylthioether / Aryl thioether / Aryl ketone / Aryl alkyl ketone / Benzenoid / Vinylogous thioester / Ketone / Thioether / Monocarboxylic acid or derivatives
Molecular Framework: Aromatic heteropolycyclic compounds
External Descriptors: Not Available

Enzymes

Details1. UDP-glucuronosyltransferase 2B7

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Glucuronosyltransferase activity
Specific Function: UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name: UGT2B7
Uniprot ID: P16662
Uniprot Name: UDP-glucuronosyltransferase 2B7
Molecular Weight: 60694.12 Da

References

Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Details2. Cytochrome P450 2C9

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Steroid hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP2C9
Uniprot ID: P11712
Uniprot Name: Cytochrome P450 2C9
Molecular Weight: 55627.365 Da

References

Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Details3. Prostaglandin G/H synthase 1

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Prostaglandin-endoperoxide synthase activity
Specific Function: Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name: PTGS1
Uniprot ID: P23219
Uniprot Name: Prostaglandin G/H synthase 1
Molecular Weight: 68685.82 Da

References

Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Drug created on August 31, 2010 14:54 / Updated on August 02, 2018 05:39

Zaltoprofen

Identification

Structure for DB06737 (Zaltoprofen)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Enzymes

References

References

References